EMA finds rare spinal condition, AZ link

By Mrinalika Roy
Updated January 15 2022 - 6:01am, first published 5:59am
An EMA panel says a causal relationship between AstraZeneca and transverse myelitis is possible.
An EMA panel says a causal relationship between AstraZeneca and transverse myelitis is possible.

A safety panel of the European drug regulator has recommended adding a rare spinal inflammation called transverse myelitis as a side effect of AstraZeneca's COVID-19 vaccine.

Subscribe now for unlimited access.

$0/

(min cost $0)

or signup to continue reading

See subscription options

Get the latest Canberra news in your inbox

Sign up for our newsletter to stay up to date.

We care about the protection of your data. Read our Privacy Policy.